Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) Non Operating Income (2024 - 2025)

Humacyte has reported Non Operating Income over the past 2 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Non Operating Income at $6.0 million for Q4 2025, down 15.61% from a year ago — trailing twelve months through Dec 2025 was $67.3 million (up 296.2% YoY), and the annual figure for FY2025 was $67.3 million, up 296.2%.
  • Non Operating Income for Q4 2025 was $6.0 million at Humacyte, down from $6.9 million in the prior quarter.
  • Over the last five years, Non Operating Income for HUMA hit a ceiling of $62.3 million in Q1 2025 and a floor of -$27.2 million in Q2 2024.